Table 2.
Stratified analysis of the MDR1 3435C > T polymorphism on cancer risk
| Genetic model | Homozygote | Heterozygote | Dominant model | Recessive model | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |
Sample size (case/control) |
OR (95% CI) |
ph |
I2 (%) |
OR (95% CI) |
ph |
I2 (%) |
OR (95% CI) |
ph |
I2 (%) |
OR (95% CI) |
ph |
I2 (%) |
| |
|
TT vs. CC |
|
|
TC vs. CC |
|
|
TT + TC vs. CC |
|
|
TT vs. TC + CC |
|
|
| C3435T |
52(15789/20274) |
1.286(1.123-1.474) |
0.000 |
71.30% |
1.126(1.020-1.244) |
0.000 |
58.20% |
1.176(1.068-1.295) |
0.000 |
61.60% |
1.191(1.065-1.333) |
0.000 |
73.00% |
| Cancer types | |||||||||||||
| Acute lymphoblastic leukemia (ALL) |
8(1381/1459) |
1.890(1.177-3.037) |
0.000 |
77.60% |
0.981(0.683-1.410) |
0.001 |
70.10% |
1.240(1.046-1.470) |
0.153 |
34.50% |
1.829(1.095-3.054) |
0.000 |
87.30% |
| Colorectal cancer |
14(6362/7274) |
1.047(0.875-1.254) |
0.006 |
55.90% |
1.053(0.906-1.224) |
0.013 |
51.80% |
1.054(0.907-1.225) |
0.005 |
56.60% |
1.014(0.939-1.094) |
0.037 |
44.50% |
| breast cancer |
9(5073/7498) |
1.187(0.869-1.621) |
0.001 |
69.30% |
0.992(0.912-1.079) |
0.190 |
28.70% |
1.098(0.906-1.331) |
0.024 |
54.80% |
1.134(0.905-1.420) |
0.017 |
57.10% |
| Ethnicity | |||||||||||||
| Caucasian |
33(12146/15989) |
1.276(1.112-1.464) |
0.000 |
60.40% |
1.172(1.047-1.313) |
0.000 |
54.9% |
1.212 (1.083-1.357) |
0.000 |
60.2% |
1.062 (1.005-1.122) |
0.001 |
47.7% |
| Asian |
17(2966/3418) |
1.314(0.894-1.933) |
0.000 |
80.4% |
1.072(0.837-1.374) |
0.000 |
67.4% |
1.153(0.915-1.453) |
0.000 |
67.9% |
1.236(0.867-1.763) |
0.000 |
84.4% |
| Source of control | |||||||||||||
| HB |
25(5553/6173) |
1.307(1.046-1.632) |
0.000 |
69.10% |
1.090(0.913-1.302) |
0.000 |
64.60% |
1.170(1.009-1.357) |
0.001 |
54.90% |
1.221(0.995-1.498) |
0.000 |
76.80% |
| PB |
26(10143/13992) |
1.294(1.079-1.552) |
0.000 |
73.90% |
1.150(1.019-1.299) |
0.001 |
53.20% |
1.479(1.267-1.726) |
0.000 |
77.60% |
1.183(1.033-1.355) |
0.000 |
69.60% |
| TT vs. CC |
|
|
TC vs. CC |
|
|
TT + TC vs. CC |
|
|
TT vs. TC + CC |
|
|
||
| C1236T |
10(2101/2842) |
1.325(0.824-2.133) |
0.000 |
77.10% |
1.133(0.817-1.573) |
0.005 |
62.20% |
1.173(0.825-1.668) |
0.000 |
70.60% |
1.191(0.840-1.690) |
0.000 |
77.80% |
| TT + AA + TA vs. GG |
|
|
TG + TA vs. GG |
|
|
TT + AA + TA + TG + TA vs. GG |
|
|
TT + AA + TA vs. TG + TA + GG |
|
|
||
| G2677T/A |
18(3585/4351) |
1.348(1.031-1.762) |
0.000 |
68.70% |
1.096(0.986-1.218) |
0.136 |
27.50% |
1.161(1.051-1.281) |
0.019 |
45.50% |
1.278(1.022-1.597) |
0.000 |
68.00% |
| Ethnicity | |||||||||||||
| Caucasian |
11(1728/1950) |
1.363(0.921-2.016) |
0.000 |
73.60% |
1.081(0.852-1.373) |
0.029 |
50.10% |
1.149(0.899-1.467) |
0.007 |
58.80% |
1.271(0.906-1.782) |
0.000 |
74.60% |
| Asian |
6(1583/2040) |
1.642(1.340-2.012) |
0.142 |
39.50% |
1.153(0.989-1.344) |
0.804 |
0.00% |
1.273(1.101-1.471) |
0.643 |
0.00% |
1.481(1.244-1.763) |
0.192 |
32.50% |
| Source of control | |||||||||||||
| HB |
10(1489/2220) |
1.036(0.847-1.267) |
0.045 |
47.80% |
1.025(0.874-1.202) |
0.072 |
43.00% |
1.032(0.888-1.198) |
0.077 |
42.10% |
1.028(0.867-1.219) |
0.137 |
33.90% |
| PB | 7(2005/2022) | 1.641(1.018-2.646) | 0.000 | 77.20% | 1.164(1.008-1.345) | 0.418 | 0.70% | 1.284(1.122-1.470) | 0.099 | 43.80% | 1.537(0.998-2.366) | 0.000 | 80.10% |
HB: hospital-based; PB: population-based.